Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Multi-center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone (Eutropin Inj. / Eutropin Plus Inj.) Treatment With GHD, TS, CRF, SGA, ISS and PWS in Children

Next Previous
X
Search
Trial Profile

An Open, Multi-center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone (Eutropin Inj. / Eutropin Plus Inj.) Treatment With GHD, TS, CRF, SGA, ISS and PWS in Children

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somatropin (Primary)
  • Indications Prader-Willi syndrome; Renal failure; Short stature; Somatotropin deficiency; Turner's syndrome
  • Focus Adverse reactions
  • Acronyms LGS
  • Sponsors LG Chem; LG Life Sciences

    • Most Recent Events

    • 12 Mar 2022 Results assessing the growth responses to 3 years of growth hormone treatment in children and adolescents with GH deficiency published in the Journal of Korean Medical Science
    • 17 Feb 2021 Planned number of patients changed from 2000 to 6000.
    • 17 Feb 2021 Planned End Date changed from 1 Jan 2022 to 31 Dec 2032.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top